source
- FDA official says midterm elections unlikely to delay user fee reauthorization for FY 2028-2032A senior FDA official indicated that the recent midterm election results are not expected to interfere with the upcoming renewal of the agency’s user fee contracts covering fiscal years 2028 throug…
- Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunchVivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…